ZS Pharma, founded in 2008, is a privately held specialty pharmaceutical company based in Coppell, Texas and Menlo Park, CA. Our core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions.
Our lead therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late stage clinical trials.
ZS-9 is a novel agent in Phase 3 clinical trials for the treatment of hyperkalemia. The clinical development program is designed to support a comprehensive label for the treatment of acute and chronic hyperkalemia, regardless of the underlying cause. The drug is being studied in approximately 1500 hyperkalemic patients with underlying CKD, diabetes, CHF, and in those patients on cardio-renal protective RAASi therapy.
ZS-9 is a highly selective oral sorbent designed specifically to trap potassium ions over other ions throughout the GI tract. In in-vitro studies, ZS-9 was shown to have a binding capacity of up to 3.5 mEq of potassium per gram, exceeding the capacity of existing polymer-based resins. ZS-9 is an inorganic crystal and not an organic polymer resin. Thus, it is differentiated from non-selective binders that swell when in contact with water and can be poorly tolerated. This combination of high capacity, selectivity, and unique structure may allow ZS-9 to effectively, safely, and rapidly remove excess potassium and maintain normal potassium levels with a relatively low drug burden.
ZS-9 is orally administered as a tasteless, odorless powder or tablet and requires no special handling.
ZS Pharma is also pursuing the discovery of additional drug candidates that utilize selective ion-trap technology for the treatment of liver disease.